Navnath S. Gavande
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Navnath S. Gavande has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
Hariprasad Aruri
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48201, USA
7 shared publications- John J. Turchi
Department of Medicine, Indiana University School of Medicine
7 shared publications - Narva Deshwar Kushwaha
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201, USA
7 shared publications Jeremy M. Kelm
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
4 shared publications- Pamela L. Mendoza-Munoz
Department of Medicine, Indiana University School of Medicine (IUSM), Indianapolis, IN 46202, USA
4 shared publications - Ladislau C. Kovari
Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, MI, 48201, USA
3 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Beyond the Algorithm: Artificial Intelligence in Drug Discovery from Code to Clinic
Machine learning (ML) and artificial intelligence (AI) are revolutionizing drug discovery, transforming an inefficient system of trial and error into one based on predictive modeling and data analysis. This comprehensive review on the growing role of computational techniques and tools considers every stage of the traditional drug development pipeline. This paper discusses how novel frameworks, high-throughput data analysis, and molecular dynamics simulations advance the discovery process, from target identification and molecular screening to pharmacokinetic profiling and candidate prioritization for clinical trials. By analyzing a wide range of recent studies, this review demonstrates that these approaches significantly reduce the time required to generate new chemical entities. This paper focuses on the relation between curating data, designing models, and validating experimental results, which together determine the reproducibility and usability of computational outputs. Even though computational methods have yielded many successes, their application is limited by several challenges. Only when paired with high-quality experimental data and interdisciplinary expertise can these methods substantially reduce the time, cost, and uncertainty associated with drug discovery and development. Limitations, including poor data quality, inconsistent data reporting, and limited diversity in chemical and biological databases, continue to constrain accuracy. The lack of interpretability in the results of computational systems complicates regulatory evaluation and broader acceptance within the scientific community. Addressing these challenges involves data standardization, clear benchmarking, and integrating experimental feedback into models. All in all, the findings demonstrate that computational drug discovery is moving from its exploratory phase to a more important role in pharmaceutical research, and future discovery pipelines will increasingly depend on computational frameworks.
- 12 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBeyond the Algorithm: Artificial Intelligence in Drug Discovery from Code to Clinic
Machine learning (ML) and artificial intelligence (AI) are revolutionizing drug discovery, transforming an inefficient system of trial and error into one based on predictive modeling and data analysis. This comprehensive review on the growing role of computational techniques and tools considers every stage of the traditional drug development pipeline. This paper discusses how novel frameworks, high-throughput data analysis, and molecular dynamics simulations advance the discovery process, from target identification and molecular screening to pharmacokinetic profiling and candidate prioritization for clinical trials. By analyzing a wide range of recent studies, this review demonstrates that these approaches significantly reduce the time required to generate new chemical entities. This paper focuses on the relation between curating data, designing models, and validating experimental results, which together determine the reproducibility and usability of computational outputs. Even though computational methods have yielded many successes, their application is limited by several challenges. Only when paired with high-quality experimental data and interdisciplinary expertise can these methods substantially reduce the time, cost, and uncertainty associated with drug discovery and development. Limitations, including poor data quality, inconsistent data reporting, and limited diversity in chemical and biological databases, continue to constrain accuracy. The lack of interpretability in the results of computational systems complicates regulatory evaluation and broader acceptance within the scientific community. Addressing these challenges involves data standardization, clear benchmarking, and integrating experimental feedback into models. All in all, the findings demonstrate that computational drug discovery is moving from its exploratory phase to a more important role in pharmaceutical research, and future discovery pipelines will increasingly depend on computational frameworks.
- Open Access
- 9 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Integrated Computational Design and Multistage Virtual Screening for the Prioritization of Putative USP5 Catalytic-Cleft Inhibitors
Ubiquitin-specific protease 5 (USP5) processes unanchored polyubiquitin and has been linked to cancer-associated signaling. We developed a computer-aided workflow to generate and rank small molecules against its catalytic/substrate cleft. The starting dataset contained 26 activity records representing 19 unique compounds, ten with measured half-maximal inhibitory concentrations. Descriptor-based quantitative structure-activity relationship models underwent compound leave-one-out and scaffold-held-out validation. Ten chemical-enumeration methods produced 3,646 method–product records and 3,264 unique structures. The main screen combined these structures with ten additional source-positive molecules and retained 18 compounds under strict selection criteria. A ten-compound panel, comprising nine generated structures and one known benchmark, underwent corrected AutoDock Vina docking against two USP5 receptor copies. The primary and repeated-seed campaigns produced 800 recorded modes. Standard-precision (SP) and extra-precision (XP) Glide docking independently evaluated the prepared ligand library, followed by Prime molecular mechanics/generalized Born surface area (MM-GBSA) calculations on the XP complexes. P06 emerged as the top-ranked candidate in the three-stage consensus analysis, ranking first in SP and second in both XP and MM-GBSA evaluations. P03 achieved the most favorable mean XP docking score, whereas P09 exhibited the strongest mean MM-GBSA binding energy. P10 ranked third overall but demonstrated greater sensitivity to receptor conformation. Collectively, this integrated computational workflow establishes a prioritized hierarchy of candidate compounds targeting the USP5 catalytic/substrate-binding cleft and highlights the influence of chemical selection and receptor preparation on structure-based rankings.
- 9 November 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessIntegrated Computational Design and Multistage Virtual Screening for the Prioritization of Putative USP5 Catalytic-Cleft Inhibitors
Ubiquitin-specific protease 5 (USP5) processes unanchored polyubiquitin and has been linked to cancer-associated signaling. We developed a computer-aided workflow to generate and rank small molecules against its catalytic/substrate cleft. The starting dataset contained 26 activity records representing 19 unique compounds, ten with measured half-maximal inhibitory concentrations. Descriptor-based quantitative structure-activity relationship models underwent compound leave-one-out and scaffold-held-out validation. Ten chemical-enumeration methods produced 3,646 method–product records and 3,264 unique structures. The main screen combined these structures with ten additional source-positive molecules and retained 18 compounds under strict selection criteria. A ten-compound panel, comprising nine generated structures and one known benchmark, underwent corrected AutoDock Vina docking against two USP5 receptor copies. The primary and repeated-seed campaigns produced 800 recorded modes. Standard-precision (SP) and extra-precision (XP) Glide docking independently evaluated the prepared ligand library, followed by Prime molecular mechanics/generalized Born surface area (MM-GBSA) calculations on the XP complexes. P06 emerged as the top-ranked candidate in the three-stage consensus analysis, ranking first in SP and second in both XP and MM-GBSA evaluations. P03 achieved the most favorable mean XP docking score, whereas P09 exhibited the strongest mean MM-GBSA binding energy. P10 ranked third overall but demonstrated greater sensitivity to receptor conformation. Collectively, this integrated computational workflow establishes a prioritized hierarchy of candidate compounds targeting the USP5 catalytic/substrate-binding cleft and highlights the influence of chemical selection and receptor preparation on structure-based rankings.
- Open Access
- 10 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (11) , 5534-5561
Design, synthesis, and structure–activity relationship studies of 4-substituted phenylpyrazolidinone derivatives as potent Ku70/80 targeted DNA-PK inhibitors
The Ku70–Ku80 (Ku) heterodimer complex plays a central role in the non-homologous end joining (NHEJ) double-strand break (DSB) repair pathway and the DNA damage response (DDR). Like DNA–PK, Ku is a promising drug target for cancer treatment when combined with radiotherapy or DSB-inducing agents. We have previously reported the first-in-class, early-generation, highly potent, and specific Ku–DNA binding inhibitors (Ku-DBi's) that block the Ku interaction with DNA and inhibit DNA-PK kinase activity. These early-generation Ku-DBi's also inhibit cellular DNA-PK, NHEJ-catalyzed DSB repair, sensitize non-small cell lung cancer (NSCLC) cells to DSB-inducing agents, and potentiate the cellular effects of these agents via p53 phosphorylation through the activation of the ATM pathway. In this study, we report a comprehensive structure–activity relationship (SAR) analysis around the initial X80 hit molecule to develop highly potent Ku-DBi's. Early generation Ku-DBi's display a potent Ku–DNA binding inhibitory activity with a range of 2 to 6 μM, and DNA-PK inhibitory activity in the nanomolar range of approximately 110 nM. Microscale thermophoresis assay shows that these compounds inhibit Ku70–Ku80 binding to DNA with a Kd value of 0.4–6.4 μM. The thermal stability analysis also supports the notion that these Ku-DBi's bind to the Ku as measured by nanoDSF (Differential Scanning Fluorimetry), which is consistent with the observed SAR trends. These Ku-DBi's may serve as candidate compounds for further modification and development as anticancer therapeutics in combination with radiotherapy or DSB-inducing agents to treat certain DNA repair-deficient cancers.
- 10 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (11) , 5534-5561
Open AccessDesign, synthesis, and structure–activity relationship studies of 4-substituted phenylpyrazolidinone derivatives as potent Ku70/80 targeted DNA-PK inhibitors
The Ku70–Ku80 (Ku) heterodimer complex plays a central role in the non-homologous end joining (NHEJ) double-strand break (DSB) repair pathway and the DNA damage response (DDR). Like DNA–PK, Ku is a promising drug target for cancer treatment when combined with radiotherapy or DSB-inducing agents. We have previously reported the first-in-class, early-generation, highly potent, and specific Ku–DNA binding inhibitors (Ku-DBi's) that block the Ku interaction with DNA and inhibit DNA-PK kinase activity. These early-generation Ku-DBi's also inhibit cellular DNA-PK, NHEJ-catalyzed DSB repair, sensitize non-small cell lung cancer (NSCLC) cells to DSB-inducing agents, and potentiate the cellular effects of these agents via p53 phosphorylation through the activation of the ATM pathway. In this study, we report a comprehensive structure–activity relationship (SAR) analysis around the initial X80 hit molecule to develop highly potent Ku-DBi's. Early generation Ku-DBi's display a potent Ku–DNA binding inhibitory activity with a range of 2 to 6 μM, and DNA-PK inhibitory activity in the nanomolar range of approximately 110 nM. Microscale thermophoresis assay shows that these compounds inhibit Ku70–Ku80 binding to DNA with a Kd value of 0.4–6.4 μM. The thermal stability analysis also supports the notion that these Ku-DBi's bind to the Ku as measured by nanoDSF (Differential Scanning Fluorimetry), which is consistent with the observed SAR trends. These Ku-DBi's may serve as candidate compounds for further modification and development as anticancer therapeutics in combination with radiotherapy or DSB-inducing agents to treat certain DNA repair-deficient cancers.
- Open Access
- 3 September 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Structure-Based Design and Development of 2-Oxindole Derivatives as Next Generation Ku-DNA Binding Inhibitors (Ku-DBi’s) for Cancer Therapy.
The Ku70/Ku80 heterodimer (Ku) plays a key role in the non-homologous end joining (NHEJ) pathway by recognizing DNA double-strand breaks (DSBs) and recruiting DNA-PKcs to initiate DNA repair. Aberrant activation of this pathway contributes to therapy resistance in cancer by enhancing DNA repair capacity. Although DNA-PK inhibitors show strong in vitro potency, their clinical advancement has been hindered by poor selectivity, low tumor accumulation, and systemic toxicity, preventing the achievement of maximum tolerated doses. To address these limitations, we targeted the Ku-DNA interaction and were the first to develop Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku70/Ku80 interaction with DNA, thereby inhibiting DNA-PK activation and downstream repair. Our earlier Ku-DBi’s exhibited potent inhibitory activity and selectivity, but their in vivo utility was restricted by poor solubility, metabolic stability, and limited cellular permeability. In this study, we identified lead compounds with a novel 2-oxindole scaffold through iterative structure-activity relationship (SAR) optimization. This series of compounds maintained potent biochemical activity while exhibiting enhanced solubility, cellular permeability, and metabolic stability. Lead candidates 34 (GL-3395), 35 (GL-3392), 47 (GL-3367), and 53 (GL-3609) inhibited Ku-DNA binding at 1-4 µM and DNA-PK at 0.30-0.80 µM. Notably, compounds 19 (GL-3391), 35 (GL-3392), and 38 (GL-3366) exhibited significantly enhanced cellular uptake in both A549 and H460 cells under standard conditions without serum-free media. Molecular docking and in silico ADME profiling supported their favorable binding and drug-like properties. These findings offer a promising foundation for advancing Ku-DBi as an adjuvant therapy for DNA damage-based cancer treatment.
- 3 September 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure-Based Design and Development of 2-Oxindole Derivatives as Next Generation Ku-DNA Binding Inhibitors (Ku-DBi’s) for Cancer Therapy.
The Ku70/Ku80 heterodimer (Ku) plays a key role in the non-homologous end joining (NHEJ) pathway by recognizing DNA double-strand breaks (DSBs) and recruiting DNA-PKcs to initiate DNA repair. Aberrant activation of this pathway contributes to therapy resistance in cancer by enhancing DNA repair capacity. Although DNA-PK inhibitors show strong in vitro potency, their clinical advancement has been hindered by poor selectivity, low tumor accumulation, and systemic toxicity, preventing the achievement of maximum tolerated doses. To address these limitations, we targeted the Ku-DNA interaction and were the first to develop Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku70/Ku80 interaction with DNA, thereby inhibiting DNA-PK activation and downstream repair. Our earlier Ku-DBi’s exhibited potent inhibitory activity and selectivity, but their in vivo utility was restricted by poor solubility, metabolic stability, and limited cellular permeability. In this study, we identified lead compounds with a novel 2-oxindole scaffold through iterative structure-activity relationship (SAR) optimization. This series of compounds maintained potent biochemical activity while exhibiting enhanced solubility, cellular permeability, and metabolic stability. Lead candidates 34 (GL-3395), 35 (GL-3392), 47 (GL-3367), and 53 (GL-3609) inhibited Ku-DNA binding at 1-4 µM and DNA-PK at 0.30-0.80 µM. Notably, compounds 19 (GL-3391), 35 (GL-3392), and 38 (GL-3366) exhibited significantly enhanced cellular uptake in both A549 and H460 cells under standard conditions without serum-free media. Molecular docking and in silico ADME profiling supported their favorable binding and drug-like properties. These findings offer a promising foundation for advancing Ku-DBi as an adjuvant therapy for DNA damage-based cancer treatment.
- Open Access
- 28 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Structure-Guided Design of Potent and Selective Covalent Inhibitors of SARS-CoV-1 and SARS-CoV-2 Papain-like Proteases with Antiviral Activity.
The papain-like protease (PLpro), one of two essential cysteine proteases in human coronaviruses, is indispensable for viral polyprotein processing and immune evasion through deubiquitination and deIS-Gylation of host proteins. This dual role makes PLpro an attractive antiviral target, either as a monother-apy or in combination with other direct-acting antivirals. Guided by structural insights, we designed and synthesized covalent inhibitors that exploit two key binding elements: Glu167 in the α-cleft (Site I), which mediates recognition of ubiquitin and ISG15, and the BL2 hydrophobic groove, which stabilizes inhibitor binding and shapes selectivity. The optimized inhibitors exhibited potent enzymatic inhibition (IC₅₀ = 25-100 nM), strong protein stabilization (ΔTₘ > 20 °C), and submicromolar antiviral activity in SARS-CoV-2–infected A549-ACE2 cells (EC₅₀ = 130-350 nM), with no measurable cytotoxicity (CC₅₀ > 10 µM). Lead compounds 8 (GL-612), 67 (GL-508), and 10 (GL-637) efficiently inactivated PLpro, with GL-637 achieving a kinact/KI > 18,000 M⁻¹ s⁻¹, and demonstrated selectivity by sparing host deubiquitinases USP7 and USP14 at concentrations up to 30 µM. Docking and mechanistic analyses revealed that cyclic amine-substituted benzamides reinforced electrostatic interactions with Glu167, while the (S)-3-fluoropyrrolidin-1-methyl-phenylthiophene scaffold anchored the BL2 groove, disrupting recognition of ubiquitin and ISG15 substrates. This dual engagement strategy improved covalent efficiency, strength-ened binding affinity, and translated into superior antiviral potency compared with benchmark compound 4. Collectively, these findings identify GL-612, GL-508, and GL-637 as first-in-class covalent PLpro in-hibitors that uniquely combine Glu167 engagement with BL2 groove occupancy, providing a strong foundation for broad-spectrum coronavirus therapeutic against current and emerging coronaviruses.
- 28 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure-Guided Design of Potent and Selective Covalent Inhibitors of SARS-CoV-1 and SARS-CoV-2 Papain-like Proteases with Antiviral Activity.
The papain-like protease (PLpro), one of two essential cysteine proteases in human coronaviruses, is indispensable for viral polyprotein processing and immune evasion through deubiquitination and deIS-Gylation of host proteins. This dual role makes PLpro an attractive antiviral target, either as a monother-apy or in combination with other direct-acting antivirals. Guided by structural insights, we designed and synthesized covalent inhibitors that exploit two key binding elements: Glu167 in the α-cleft (Site I), which mediates recognition of ubiquitin and ISG15, and the BL2 hydrophobic groove, which stabilizes inhibitor binding and shapes selectivity. The optimized inhibitors exhibited potent enzymatic inhibition (IC₅₀ = 25-100 nM), strong protein stabilization (ΔTₘ > 20 °C), and submicromolar antiviral activity in SARS-CoV-2–infected A549-ACE2 cells (EC₅₀ = 130-350 nM), with no measurable cytotoxicity (CC₅₀ > 10 µM). Lead compounds 8 (GL-612), 67 (GL-508), and 10 (GL-637) efficiently inactivated PLpro, with GL-637 achieving a kinact/KI > 18,000 M⁻¹ s⁻¹, and demonstrated selectivity by sparing host deubiquitinases USP7 and USP14 at concentrations up to 30 µM. Docking and mechanistic analyses revealed that cyclic amine-substituted benzamides reinforced electrostatic interactions with Glu167, while the (S)-3-fluoropyrrolidin-1-methyl-phenylthiophene scaffold anchored the BL2 groove, disrupting recognition of ubiquitin and ISG15 substrates. This dual engagement strategy improved covalent efficiency, strength-ened binding affinity, and translated into superior antiviral potency compared with benchmark compound 4. Collectively, these findings identify GL-612, GL-508, and GL-637 as first-in-class covalent PLpro in-hibitors that uniquely combine Glu167 engagement with BL2 groove occupancy, providing a strong foundation for broad-spectrum coronavirus therapeutic against current and emerging coronaviruses.
- 26 May 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (8) , 3429-3455
Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS
KRAS G12 mutations drive aggressive cancers. Once considered undruggable, several strategies evolved in the last decade to target OFF and ON states. Approval of inhibitors and the growing pipeline offer great hope to patients.
- 26 May 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (8) , 3429-3455
Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS
KRAS G12 mutations drive aggressive cancers. Once considered undruggable, several strategies evolved in the last decade to target OFF and ON states. Approval of inhibitors and the growing pipeline offer great hope to patients.
- Open Access
- 21 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Design, Synthesis, and Structure–Activity Relationship Studies of 4-substituted Phenylpyrazolidinone Derivatives as Potent Ku70/80 Targeted DNA-PK Inhibitors
The Ku70-Ku80 (Ku) heterodimer complex plays a central role in the non-homologous end joining (NHEJ) double-strand break (DSB) repair pathway and the DNA damage response (DDR). Like DNA-PK, Ku is a promising drug target for cancer treatment when combined with radiotherapy or DSB-inducing agents. We have previously reported the first-in-class early-generation highly potent and specific Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku interaction with DNA and inhibit DNA-PK kinase activity. These early-generation Ku-DBi’s also inhibit cellular DNA-PK, NHEJ-catalyzed DSB repair, sensitize non-small cell lung cancer (NSCLC) cells to DSB-inducing agents, and potentiate the cellular effects of these agents via p53 phosphorylation through the activation of the ATM pathway. In this study, we report a comprehensive structure-activity relationship (SAR) around the initial X80 hit molecule to develop highly potent Ku-DBi’s. Early generation Ku-DBi’s display a potent Ku-DNA binding inhibitory activity with a range of 2 to 6 μM, and DNA-PK inhibitory activity in the nanomolar range of approximately 110 nM. Microscale thermophoresis assay shows that these compounds inhibit Ku70-Ku80 binding to DNA with a Kd value of 0.4-6.4 μM. The thermal stability analysis also supports the notion that these Ku-DBi’s bind to the Ku as measured by nano DSF, which is consistent with the observed SAR trends. These Ku-DBi’s may serve as candidate compounds for further modification and development as anticancer therapeutics in combination with radiotherapy or DSB-inducing agents to treat certain DNA repair-deficient cancers.
- 21 February 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDesign, Synthesis, and Structure–Activity Relationship Studies of 4-substituted Phenylpyrazolidinone Derivatives as Potent Ku70/80 Targeted DNA-PK Inhibitors
The Ku70-Ku80 (Ku) heterodimer complex plays a central role in the non-homologous end joining (NHEJ) double-strand break (DSB) repair pathway and the DNA damage response (DDR). Like DNA-PK, Ku is a promising drug target for cancer treatment when combined with radiotherapy or DSB-inducing agents. We have previously reported the first-in-class early-generation highly potent and specific Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku interaction with DNA and inhibit DNA-PK kinase activity. These early-generation Ku-DBi’s also inhibit cellular DNA-PK, NHEJ-catalyzed DSB repair, sensitize non-small cell lung cancer (NSCLC) cells to DSB-inducing agents, and potentiate the cellular effects of these agents via p53 phosphorylation through the activation of the ATM pathway. In this study, we report a comprehensive structure-activity relationship (SAR) around the initial X80 hit molecule to develop highly potent Ku-DBi’s. Early generation Ku-DBi’s display a potent Ku-DNA binding inhibitory activity with a range of 2 to 6 μM, and DNA-PK inhibitory activity in the nanomolar range of approximately 110 nM. Microscale thermophoresis assay shows that these compounds inhibit Ku70-Ku80 binding to DNA with a Kd value of 0.4-6.4 μM. The thermal stability analysis also supports the notion that these Ku-DBi’s bind to the Ku as measured by nano DSF, which is consistent with the observed SAR trends. These Ku-DBi’s may serve as candidate compounds for further modification and development as anticancer therapeutics in combination with radiotherapy or DSB-inducing agents to treat certain DNA repair-deficient cancers.
- Open Access
- 7 February 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 240
Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects
Cancer management has traditionally depended on chemotherapy as the mainstay of treatment; however, recent advancements in targeted therapies and immunotherapies have offered new options. Ubiquitin-specific proteases (USPs) have emerged as promising therapeutic targets in cancer treatment due to their crucial roles in regulating protein homeostasis and various essential cellular processes. This review covers the following: (1) the structural and functional characteristics of USPs, highlighting their involvement in key cancer-related pathways, and (2) the discovery, chemical structures, mechanisms of action, and potential clinical implications of USP inhibitors in cancer therapy. Particular attention is given to the role of USP inhibitors in enhancing cancer immunotherapy, e.g., modulation of the tumor microenvironment, effect on regulatory T cell function, and influence on immune checkpoint pathways. Furthermore, this review summarizes the current progress and challenges of clinical trials involving USP inhibitors as cancer therapy. We also discuss the complexities of achieving target selectivity, the ongoing efforts to develop more specific and potent USP inhibitors, and the potential of USP inhibitors to overcome drug resistance and synergize with existing cancer treatments. We finally provide a perspective on future directions in targeting USPs, including the potential for personalized medicine based on specific gene mutations, underscoring their significant potential for enhancing cancer treatment. By elucidating their mechanisms of action, clinical progress, and potential future applications, we hope that this review could serve as a useful resource for both basic scientists and clinicians in the field of cancer therapeutics.
- 7 February 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 240
Open AccessUbiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects
Cancer management has traditionally depended on chemotherapy as the mainstay of treatment; however, recent advancements in targeted therapies and immunotherapies have offered new options. Ubiquitin-specific proteases (USPs) have emerged as promising therapeutic targets in cancer treatment due to their crucial roles in regulating protein homeostasis and various essential cellular processes. This review covers the following: (1) the structural and functional characteristics of USPs, highlighting their involvement in key cancer-related pathways, and (2) the discovery, chemical structures, mechanisms of action, and potential clinical implications of USP inhibitors in cancer therapy. Particular attention is given to the role of USP inhibitors in enhancing cancer immunotherapy, e.g., modulation of the tumor microenvironment, effect on regulatory T cell function, and influence on immune checkpoint pathways. Furthermore, this review summarizes the current progress and challenges of clinical trials involving USP inhibitors as cancer therapy. We also discuss the complexities of achieving target selectivity, the ongoing efforts to develop more specific and potent USP inhibitors, and the potential of USP inhibitors to overcome drug resistance and synergize with existing cancer treatments. We finally provide a perspective on future directions in targeting USPs, including the potential for personalized medicine based on specific gene mutations, underscoring their significant potential for enhancing cancer treatment. By elucidating their mechanisms of action, clinical progress, and potential future applications, we hope that this review could serve as a useful resource for both basic scientists and clinicians in the field of cancer therapeutics.
- 29 December 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 20 (2) , 155-166
Enhanced safety and efficacy profile of CD40 antibody upon encapsulation in pHe-triggered membrane-adhesive nanoliposomes
To develop pH (pHe)-triggered membrane adhesive nanoliposome (pHTANL) of CD40a to enhance anti-tumor activity in pancreatic cancer while reducing systemic toxicity. A small library of nanoliposomes (NL) with various lipid compositions were synthesized to prepare pH (pHe)-triggered membrane adhesive nanoliposome (pHTANL). Physical and functional characterization of pHTANL-CD40a was performed via dynamic light scattering (DLS), Transmission Electron Microscopy (TEM), confocal microscopy, and flow cytometry. In vivo studies were performed using PDAC (Panc02) transplanted mice. Tumor tissue was analyzed by flow cytometry, and plasma cytokines and liver enzymes were analyzed by ELISA. pHTANL-CD40a reduced tumor growth, enhanced tumor immune infiltration/activation, and enhanced survival compared to vehicle and free-CD40a. Importantly, pHTANL-CD40a treatment resulted in significantly lower systemic toxicity as indicated by unchanged body weight, minimal organ deformity, and reduced serum levels of liver enzyme alanine transaminase (ALT) and inflammatory cytokine IL-6. pHTANL-CD40a is more effective than free CD40a in anti-tumor activity, especially in altering the TME immune landscape for a potential therapeutic benefit in combination with immunotherapy.
- 29 December 2024
- Published by Taylor & Francis in Nanomedicine
- Vol. 20 (2) , 155-166
Enhanced safety and efficacy profile of CD40 antibody upon encapsulation in pHe-triggered membrane-adhesive nanoliposomes
To develop pH (pHe)-triggered membrane adhesive nanoliposome (pHTANL) of CD40a to enhance anti-tumor activity in pancreatic cancer while reducing systemic toxicity. A small library of nanoliposomes (NL) with various lipid compositions were synthesized to prepare pH (pHe)-triggered membrane adhesive nanoliposome (pHTANL). Physical and functional characterization of pHTANL-CD40a was performed via dynamic light scattering (DLS), Transmission Electron Microscopy (TEM), confocal microscopy, and flow cytometry. In vivo studies were performed using PDAC (Panc02) transplanted mice. Tumor tissue was analyzed by flow cytometry, and plasma cytokines and liver enzymes were analyzed by ELISA. pHTANL-CD40a reduced tumor growth, enhanced tumor immune infiltration/activation, and enhanced survival compared to vehicle and free-CD40a. Importantly, pHTANL-CD40a treatment resulted in significantly lower systemic toxicity as indicated by unchanged body weight, minimal organ deformity, and reduced serum levels of liver enzyme alanine transaminase (ALT) and inflammatory cytokine IL-6. pHTANL-CD40a is more effective than free CD40a in anti-tumor activity, especially in altering the TME immune landscape for a potential therapeutic benefit in combination with immunotherapy.